CD8A and breast carcinoma: In a mouse model of breast cancer, tumors treated with anti-CAF therapy transitioned from a Th2 to Th1 response with a prominent increase in CD8+ T cells and a prominent decrease in tumor-associated macrophages, myeloid-derived suppressor cells, and regulatory T cells [32].